Research Triumphs in Liver Disease Reversal
Dr. Arun Sanyal, head of the VCU Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, talks about recent clinical trials engaging 800 participants.
In a promising study published in the New England Journal of Medicine, researchers demonstrated that semaglutide injections could reverse severe liver disease.
Semaglutide, an established treatment for type 2 diabetes, was administered to participants suffering from a critical liver condition known as metabolic dysfunction-associated steatohepatitis (MASH).
“This is a significant advancement in this field,” Dr. Sanyal shared in a video from VCU. “When treating fatty liver disease, we now have more options for patients.”
MASH is a serious variant of metabolic dysfunction-associated fatty liver disease, formerly termed non-alcoholic fatty liver disease, according to WebMD.
Excess fat accumulation in the liver is what characterizes both MASH and MASLD, and this situation poses real dangers.
A press release on the study emphasized that accumulating liver fat can eventually lead to inflammation and could progress to more severe issues like liver fibrosis, cirrhosis, or even cancer.
Researchers investigated semaglutide due to its ability to reduce fat and scarring in patients with MASH in prior studies.
From 2021 to 2023, 800 participants were randomly chosen from 37 countries, receiving either a semaglutide injection or a placebo. The group consisted of over half with type 2 diabetes, and around 75% were categorized as obese.
After 72 weeks of treatment, a remarkable 62.9% of those treated with semaglutide saw reductions in liver inflammation and fat accumulation, whereas only 34.3% in the placebo group experienced similar improvements.
“Under a microscope, these patients’ liver conditions appeared significantly improved,” Sanyal noted.
Interestingly, 36.8% of the semaglutide group showed improvement in liver fibrosis, while only 22.4% in the placebo group did.
In terms of health metrics, participants using semaglutide also experienced a weight loss of about 10.5%, along with improved liver enzyme levels.
“After 16 years on GLP-1 treatment, these results are truly exciting.”
However, some participants in the semaglutide group reported side effects such as nausea, diarrhea, constipation, and vomiting.
Anna Windle, a senior vice president at Novo Nordisk, indicated that they are keen to explore how semaglutide can be further utilized in both metabolic and cardiovascular health contexts, especially regarding MASH, which offers limited treatment avenues for patients and clinicians alike.
“We’re thrilled to see these findings highlighted in NEJM, and they represent hope for patients. We aim to collaborate with regulators to potentially roll out this cutting-edge treatment,” she remarked.
Dr. Philip Newsom, who leads the liver research at King’s College, expressed cautious optimism about the results, stating, “These findings should be approached carefully, but the analysis indicates that semaglutide could be a valuable tool against this advanced liver disease.”
Dr. Sanyal added that semaglutide had previously shown benefits for weight management, diabetes, and heart health, and now liver disease can be included in that positive list.
Looking forward, researchers plan to gather data from around 1,200 participants in 37 countries over five years to further assess the long-term effects of semaglutide on liver health.
